Evaluation of antiviral T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India.
AIDS Vaccines
/ administration & dosage
Antiviral Agents
/ administration & dosage
Female
HIV Infections
/ immunology
HIV-1
/ classification
Humans
Immunologic Memory
/ drug effects
Male
Stem Cells
/ drug effects
T-Lymphocyte Subsets
/ drug effects
Vaccination
Virus Replication
/ drug effects
Volunteers
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
11
2019
accepted:
06
02
2020
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
10
5
2020
Statut:
epublish
Résumé
T cells play an important role in controlling viral replication during HIV infection. An effective vaccine should, therefore, lead to the induction of a strong and early viral-specific CD8+ T cell response. While polyfunctional T cell responses are thought to be important contributors to the antiviral response, there is evidence to show that polyfunctional HIV- specific CD8+ T cells are just a small fraction of the total HIV-specific CD8+ T cells and may be absent in many individuals who control HIV replication, suggesting that other HIV-1 specific CD8+ effector T cell subsets may be key players in HIV control. Stem cell-like memory T cells (TSCM) are a subset of T cells with a long half-life and self-renewal capacity. They serve as key reservoirs for HIV and contribute a significant barrier to HIV eradication. The present study evaluated vaccine-induced antiviral responses and TSCM cells in volunteers vaccinated with a subtype C prophylactic HIV-1 vaccine candidate administered in a prime-boost regimen. We found that ADVAX DNA prime followed by MVA boost induced significantly more peripheral CD8+ TSCM cells and higher levels of CD8+ T cell-mediated inhibition of replication of different HIV-1 clades as compared to MVA alone and placebo. These findings are novel and provide encouraging evidence to demonstrate the induction of TSCM and cytotoxic immune responses by a subtype C HIV-1 prophylactic vaccine administered using a prime-boost strategy.
Identifiants
pubmed: 32097435
doi: 10.1371/journal.pone.0229461
pii: PONE-D-19-30903
pmc: PMC7041807
doi:
Substances chimiques
AIDS Vaccines
0
Antiviral Agents
0
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229461Déclaration de conflit d'intérêts
NO authors have competing interests
Références
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007252
pubmed: 22229122
Nat Med. 2014 Feb;20(2):139-42
pubmed: 24412925
J Virol. 2014 Dec;88(23):13836-44
pubmed: 25253339
J Virol. 1997 Apr;71(4):3120-8
pubmed: 9060675
J Virol. 1999 Aug;73(8):6715-20
pubmed: 10400769
J Virol. 2007 Jan;81(1):434-8
pubmed: 17050606
Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a007351
pubmed: 23209178
mBio. 2018 Apr 10;9(2):
pubmed: 29636433
Hum Vaccin Immunother. 2017 May 4;13(5):1018-1030
pubmed: 28281871
Nat Immunol. 2004 Mar;5(3):233-6
pubmed: 14985706
AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16
pubmed: 19943789
J Virol. 1994 Sep;68(9):6103-10
pubmed: 8057491
J Virol. 2015 Aug;89(15):7829-40
pubmed: 25995260
Lancet. 2004 Mar 13;363(9412):863-6
pubmed: 15031033
F1000Res. 2017 Apr 28;6:597
pubmed: 28529718
Curr HIV/AIDS Rep. 2015 Mar;12(1):33-40
pubmed: 25578055
J Immunol. 2009 Apr 15;182(8):4751-61
pubmed: 19342652
PLoS One. 2010 Jan 25;5(1):e8617
pubmed: 20111582
Discov Med. 2010 Mar;9(46):261-6
pubmed: 20350494
J Theor Biol. 2001 Aug 21;211(4):419-32
pubmed: 11476625
J Clin Invest. 2013 Feb;123(2):594-9
pubmed: 23281401
Proc Biol Sci. 1999 Dec 22;266(1437):2523-30
pubmed: 10693824
J Exp Med. 2006 Oct 2;203(10):2281-92
pubmed: 16954372
J Exp Med. 1989 Jun 1;169(6):1993-2005
pubmed: 2471771
J Virol. 2009 Nov;83(22):11876-89
pubmed: 19726501
J Immunol. 2016 Feb 15;196(4):1568-78
pubmed: 26764034
J Infect Dis. 2008 Nov 15;198(10):1482-90
pubmed: 18808335
J Virol. 2010 May;84(10):4998-5006
pubmed: 20200250
Nature. 1994 Jun 23;369(6482):652-4
pubmed: 7516039
Nat Med. 2006 Oct;12(10):1198-202
pubmed: 16917489
J Theor Biol. 2001 Dec 7;213(3):447-59
pubmed: 11735291
J Infect Dis. 2010 Mar;201(5):720-9
pubmed: 20132004
Nat Rev Immunol. 2011 Oct 25;11(11):716
pubmed: 22025045
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13125-30
pubmed: 8917555
Nihon Rinsho. 2002 Apr;60(4):717-23
pubmed: 11968778
Immunol Rev. 2011 Jan;239(1):109-24
pubmed: 21198668
Nature. 1991 Dec 12;354(6353):453-9
pubmed: 1721107
J Exp Med. 2008 Jan 21;205(1):63-77
pubmed: 18195071
PLoS One. 2019 Mar 28;14(3):e0213911
pubmed: 30921340
Nat Med. 2011 Sep 18;17(10):1290-7
pubmed: 21926977
PLoS One. 2010 Feb 02;5(2):e9015
pubmed: 20126394
J Virol. 2004 Dec;78(23):13335-44
pubmed: 15542684
Nat Med. 2005 Dec;11(12):1299-305
pubmed: 16288282
EBioMedicine. 2014 Dec 22;2(1):46-58
pubmed: 26137533
PLoS Pathog. 2010 May 27;6(5):e1000917
pubmed: 20523897
Immunity. 2014 Jul 17;41(1):7-9
pubmed: 25035947
Nature. 2001 Apr 19;410(6831):980-7
pubmed: 11309628
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
PLoS One. 2007 Mar 28;2(3):e321
pubmed: 17389912
Philos Trans R Soc Lond B Biol Sci. 2000 Mar 29;355(1395):329-43
pubmed: 10794051
J Exp Med. 2001 Jan 15;193(2):169-80
pubmed: 11148221
PLoS One. 2013;8(2):e55831
pubmed: 23418465
Clin Exp Vaccine Res. 2016 Jan;5(1):6-11
pubmed: 26866018
PLoS One. 2018 Aug 29;13(8):e0203037
pubmed: 30157242
J Immunol. 2011 Sep 15;187(6):3391-401
pubmed: 21844392
Vaccine. 2011 Oct 26;29(46):8417-28
pubmed: 21864626
J Virol. 2012 Jun;86(12):6959-69
pubmed: 22514340
J Virol. 1994 Jul;68(7):4650-5
pubmed: 8207839
J Virol. 2008 Sep;82(17):8529-36
pubmed: 18562528
J Exp Med. 1992 Nov 1;176(5):1273-81
pubmed: 1402673
J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):403-11
pubmed: 18209683